Recent submissions

Comment · 5 years ago
Hi! This is very interesting - I had a question but more so on the business side. I don't know much about finance, but what made you decide on a fixed fee pricing model than a take rate model like a hedge fund.
Comment · 5 years ago
Comment · 8 years ago
The amount of work/effort put in will have translated to something that's more easily quantifiable/measurable like growth (what kind differs from company to company), improvement in product or even the team. Agree with tzm -- you probably know best about what metrics you'd want to share in that response
Comment · 8 years ago
There are VC firms that can help you work on an H1B, or even make you an employee in the short term. There's also programs in MA where an university can employ you on an H1B and let you work on your startup. I believe UMass Boston's VDC program is one. OPT is a completely valid option too (source: know a ton of people who have used this and have extensively spoken to attorneys about it)
Comment · 8 years ago
You can use OPT, but would suggest not to so so because it will have implications on how long you can stay in the US after graduating. CPT is another option if your college allows you to use it. Post-graduation, OPT, H1-B, B1/B2 and O1 are all viable options of varying difficulty
Comment · 8 years ago
Comment · 9 years ago
yes I emailed them, but I was wondering if there's anybody over here who could answer my question too
Comment · 9 years ago
Hi Michael, thanks for the AMA. When you evaluate an early stage biotech startup, what would you say is the most important thing that you look for? - clinically validated products, or a solid long term business model?

With Trump picking Scott Gottlieb to be the next FDA commissioner, the FDA approval process is expected to get more lenient. Would you say that YC (or investors in general) would be open to take more risks with high tech startups that do not have a clinically validated product as of now?

One more question - Given that the FDA process takes a lot of time, quite a few biotech companies often get acquired or merged with bigger companies that can afford to do so, without ever having actually gotten their product out on the market. Would you say that you look at the company's potential return in that sense when you evaluate startups? I'm not entirely sure if this question makes sense, so let me know if you want me to clarify!

Live from the official Hacker News API

A modern reader for Hacker News · SvelteKit + Skeleton